Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 26, 2023

Clinical Benefit of Avapritinib in Patients With KIT-Mutant Gastrointestinal Stromal Tumors

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies
Clin. Cancer Res 2023 Nov 30;[EPub Ahead of Print], MC Heinrich, X Zhang, RL Jones, S George, C Serrano, Y Deng, S Bauer, S Cai, X Wu, Y Zhou, K Tao, Z Zheng, J Zhang, Y Cui, H Cao, M Wang, J Hu, J Yang, J Li, L Shen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading